Benefits of immunotherapy combination persist for more than six years in advanced melanoma ...Middle East

In the longest follow-up results from a clinical trial of combination immunotherapy for metastatic melanoma, investigators report that nearly half the patients who received the drugs nivolumab and ipilimumab were alive a median of six and a half years after treatment. The results, stemming from the CheckMate 067 clinical trial, represent a new landmark in survival rates for patients with melanoma treated with immune checkpoint inhibitor drugs.

Hence then, the article about benefits of immunotherapy combination persist for more than six years in advanced melanoma was published today ( Thursday 27/05/2021 - 07:01 PM ) and is available on ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Benefits of immunotherapy combination persist for more than six years in advanced melanoma )

Also on site :

• Saks Global Secures $1.75 Billion of Committed Capital and Announces Return of Industry Veterans to Advance Transformation of Iconic Luxury Portfolio
• Another Weight Loss Surgery and a Wedding Bombshell: Spoilers From '1000-Lb Sisters' Season 8 Episode 2
• Trump-Iran latest: President threatens ‘very strong action’ if protesters are hanged after forced confessions